News Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
November 2, 2020- Top-Line Data Expected in Q1 2021 -
-
October 20, 2020- European Investment Bank and Immunic sign a financing agreement of up to €24.5 million to support the development of Immunic's lead asset, IMU-838, in moderate COVID-19
-
September 29, 2020
-
September 11, 2020- Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations -
-
August 2, 2020- Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis -
-
July 27, 2020- Study Being Conducted in Collaboration with University Hospitals Coventry and Warwickshire NHS Trust -
-
June 22, 2020
-
May 19, 2020- Presentation Will Include Preclinical Data of IMU-838 Against SARS-CoV-2 as Well as First Pharmacokinetic Data From the Ongoing Phase 1 Clinical Trial of IMU-935 -
-
April 23, 2020
-
April 21, 2020- In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 -